@Hadrian
The key point is that the very purpose of generics is to circumvent the high prices of branded product, which are caused by the dysfunctional incentives of the middle-men. So what sense would it make to have them held hostage to those channels? More to the point, what incentive would those middle-men have to push low priced generics?
Ann: Launch of Dapsone 5%, Gel in the United States, page-26
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.3¢ |
Change
-0.003(4.55%) |
Mkt cap ! $18.31M | |||
| Open | High | Low | Value | Volume |
| 6.7¢ | 6.7¢ | 6.3¢ | $34.65K | 539.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 123229 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 235749 | 3 |
View Market Depth
| Last trade - 14.04pm 18/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |